Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJun112016	Fate Therapeutics Announces Preclinical Data from Immuno-Regulatory CD34+ Cell Therapy for Autoimmune Diseases One-time Administration of Programmed Cells Demonstrates Durable Disease Correction in Type 1 Diabetes Mouse Model ToleraCyte™ Product Candidate Exhibits Enhanced Trafficking to the Pancreas and Potent Regulation of Autoreactive T Cells in Preclinical Testing Preclinical Data Package to Read All »	View HTML Fate Therapeutics Announces Preclinical Data from Immuno-Regulatory CD34+ Cell Therapy for Autoimmune Diseases 384.3 KB
Toggle SummaryAug192021	Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma 10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response; 7 Patients Achieved Complete Response, including 2 of 3 Patients Treated with FT596 in Combination with Rituximab Following Autologous CD19 CAR T-cell Therapy 8 of 11 Patients in FT516 Multi-Dose Read All »	View HTML
Toggle SummaryNov122020	Fate Therapeutics Announces Participation in Upcoming Investor Conferences SAN DIEGO , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming investor Read All »	View HTML
Toggle SummaryNov032016	Fate Therapeutics Announces Oral Presentation on Natural Killer Cell Product Candidate FATE-NK100 at the 2016 ASH Annual Meeting Five Additional Presentations to Highlight the Company's Cellular Immunotherapy Programs Read All »	View HTML Fate Therapeutics Announces Oral Presentation on Natural Killer Cell Product Candidate FATE-NK100 at the 2016 ASH Annual Meeting 23.5 KB
Toggle SummaryApr162018	Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual Meeting Press Program Off-the-Shelf CAR T-cell Product Candidate Designed to Target CD19-positive Tumor Cells and to Overcome Antigen Escape Manufacture from Master iPSC Line Enables Mass Production and Broad Accessibility without Patient Restriction AACR Press Program to Begin Today at 8:30 a.m. Read All »	View HTML
Toggle SummaryFeb262014	Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase 1b Study of PROHEMA(R) SAN DIEGO, Feb. 26, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the release of new data on the observed effects of ex vivo pharmacologic Read All »	View HTML Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase 1b Study of PROHEMA(R) 17.8 KB
Toggle SummaryDec082019	Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy FT596 as a Monotherapy Demonstrates Comparable Anti-tumor Activity to CAR19 T Cells In Vivo in Humanized Mouse Model of Lymphoma Combination of FT596 with Rituximab Shows Durable Tumor Clearance In Vivo in Preclinical Lymphoma Model Company Plans to Initiate Enrollment of First-in-human Clinical Read All »	View HTML
Toggle SummaryOct122015	Fate Therapeutics Announces Leadership Transition Scott Wolchko , a Fate Founder, to Succeed Christian Weyer as President and CEO Effective December 1, 2015 Additional Leadership Changes Enhance Fate Executive Team SAN DIEGO , Oct. 12, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the Read All »	View HTML Fate Therapeutics Announces Leadership Transition 22.8 KB
Toggle SummaryJan122015	Fate Therapeutics Announces Key 2015 Objectives for the Advancement of Programmed Cellular Therapeutics Pipeline Primary Endpoint Read-outs from Adult PUMA and Pediatric PROMPT Studies of PROHEMA in Hematologic Malignancies Expected in mid-2015 Topline Data from Pediatric PROVIDE Study of PROHEMA in Rare Inherited Metabolic Disorders Expected in 2015 IND Filing for New Programmed Mobilized Peripheral Blood Read All »	View HTML Fate Therapeutics Announces Key 2015 Objectives for the Advancement of Programmed Cellular Therapeutics Pipeline 22.5 KB
Toggle SummaryOct052016	Fate Therapeutics Announces Issuance of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions Protects Cellular Composition of Lead Immunotherapy Product Candidate ProTmune™ Covers Compositions Generated Using Ex Vivo Modulation to Enhance Stem Cell Properties SAN DIEGO, Oct. 05, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to Read All »	View HTML Fate Therapeutics Announces Issuance of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions 15.7 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.